Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439320 · ClinicalTrials.gov registry record · Phase 3
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,231
- Enrollment target
NCT02439320 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,231 participants.
The verdict
NCT02439320, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,231 participants
- Enrollment target
Study Summary
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
Interventions
- DRUG Lasmiditan 100 mg
- DRUG Lasmiditan 200 mg
- DRUG Placebo (matches lasmiditan doses)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,231 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02439320
The ClinicalTrials.gov registry entry for NCT02439320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lasmiditan 100 mg is the first listed.
NCT02439320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02439320 about?
NCT02439320 is a clinical study titled "Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:". This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
What is the current status of trial NCT02439320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,231 participants. The study started on 2015-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02439320?
The interventions under investigation include: Lasmiditan 100 mg (DRUG), Lasmiditan 200 mg (DRUG), Placebo (matches lasmiditan doses) (DRUG).
Who is sponsoring clinical trial NCT02439320?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.